A Randomized, Double-Blind, Active Controlled, Optimal Dose Titration, Multicenter Study to Evaluate the Safety and Efficacy of Oral JNS024 Extended Release (ER) in Japanese and Korean Subjects With Moderate to Severe Chronic Malignant Tumor Related Cancer Pain.

Trial Profile

A Randomized, Double-Blind, Active Controlled, Optimal Dose Titration, Multicenter Study to Evaluate the Safety and Efficacy of Oral JNS024 Extended Release (ER) in Japanese and Korean Subjects With Moderate to Severe Chronic Malignant Tumor Related Cancer Pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Tapentadol (Primary) ; Oxycodone
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jan 2012 Planned end date changed from 1 Apr 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 26 Apr 2011 Planned End Date changed from 1 Aug 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top